FGFR2 and cholangiocarcinoma: In advanced refractory cholangiocarcinoma, where FGFR2 fusions predominate2, the reversible FGFR1–FGFR3 inhibitor pemigatinib5 and the irreversible FGFR1–FGFR4 inhibitor futibatinib are approved for tumors with FGFR2 fusions or other rearrangements7.